Brazilian Oil Workers’ Strike Continues as Key Petrobras Union Rejects Proposal 
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccine Portfolio 
Boeing Secures $8.6 Billion Pentagon Contract for F-15 Jets for Israel 
Royalty Pharma Stock Rises After Acquiring Full Evrysdi Royalty Rights from PTC Therapeutics 
China’s Iron Ore Buyer Pressures Mining Giants as New Supply Shifts Market Power 
Hyundai Recalls Over 51,000 Vehicles in the U.S. Due to Fire Risk From Trailer Wiring Issue 
Winter Storm Disrupts Northeast Travel as Snow and Ice Blanket New York, New Jersey 
Citigroup to Exit Russia With Sale of AO Citibank to Renaissance Capital 
California DMV Proposes New Safety Rules for Autonomous Vehicles After Waymo Incidents 
Winter Storm Devin Triggers Massive Flight Cancellations and Travel Disruptions Across the U.S. 
Meta Acquires AI Startup Manus to Expand Advanced AI Capabilities Across Platforms 
Applied Digital Stock Rises on AI Cloud Spinoff Plan and ChronoScale Launch 
Hanwha Signals Readiness to Build Nuclear-Powered Submarines at Philly Shipyard for U.S. Navy 
Vietnam’s EV Taxi Giant GSM Eyes Hong Kong IPO With $2–3 Billion Valuation 
TSMC Honors Japanese Chip Equipment Makers With 2025 Supplier Awards 
Nvidia to Acquire Groq in $20 Billion Deal to Boost AI Chip Dominance 
Trump Administration Probes Corporate DEI Programs, Raising Questions for Google Stock 
SAN DIEGO and TORONTO, March 03, 2016 -- Aptose Biosciences Inc. (NASDAQ:APTO) (TSX:APS), a clinical-stage company developing new therapeutics and molecular diagnostics that target the underlying mechanisms of cancer, today announced that William G. Rice, Ph.D., Chairman, President and Chief Executive Officer, will present at the following upcoming conferences:
- Cowen & Company 36th Annual Healthcare Conference
Aptose’s corporate presentation is scheduled to take place at 2:00 p.m. ET on Monday, March 7, 2016 in Boston, MA. A corresponding live webcast of the presentation can be accessed by visiting:
- 28th Annual ROTH Conference
Aptose’s corporate presentation is scheduled to take place at 10:30 a.m. ET on Monday, March 14, 2016 in Dana Point, CA. A corresponding live webcast of the presentation can be accessed by visiting:
The audio webcasts will be archived shortly after the live event and will be available for 90 days through the Aptose website at www.aptose.com.
About Aptose Biosciences
Aptose Biosciences is a clinical-stage biotechnology company committed to discovering and developing personalized therapies addressing unmet medical needs in oncology. Aptose is advancing new therapeutics focused on novel cellular targets on the leading edge of cancer research coupled with validated biomarkers to identify the optimal patient population for our products. The company's small molecule cancer therapeutics pipeline includes products designed to provide additive or synergistic efficacy with existing anti-cancer therapies and regimens without overlapping toxicities. Aptose Biosciences Inc. is listed on NASDAQ under the symbol APTO and on the TSX under the symbol APS. For further information, please visit www.aptose.com.
For further information, please contact: Aptose Biosciences Greg Chow, CFO 647-479-9828 [email protected] BCC Partners Karen L. Bergman or Susan Pietropaolo 650-575-1509 or 845-638-6290 [email protected] or [email protected]
